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Abstract: Objectives
To compare the experience of 4 UK Centres in the use of intradermal microbubbles
and contrast enhanced ultrasound (CEUS) to pre-operatively identify and biopsy
sentinel lymph nodes (SLN) in patients with breast cancer.
Methods
In all centres, breast cancer patients had a microbubble/ CEUS SLN core biopsy prior
to axillary surgery and patients in Centres 1 and 2 had a normal grey-scale axillary
ultrasound. Data was collected between 2010 and 2016; 1361 from Centre 1
(prospective, sequential), 376 from Centre 2 (retrospective, sequential), 122 from
Centre 3 (retrospective, selected) and 48 from Centre 4 (prospective, selected).
Results
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SLN were successfully core biopsied in 80% (Centre 1), 79.6% (Centre 2), 77.5%
(Centre 3) and 88% (Centre 4). The sensitivities to identify all SLN metastases were
46.9% (95% CI 39.4-55.1), 52.5% (95% CI 39.1-65.7), 46.4% (95% CI 27.5-66.1) and
45.5% (95% CI 16.7-76.6) respectively. Specificities; 99.7% (95% CI 98.9-100), 98.1%
(95% CI 94.5-99.6), 100% (95% CI 93.2-100%) and 96.3% (95% CI 81-99.9)
respectively. Negative predictive values; 87.0% (95% CI 84.3-89.3), 84.5% (95% CI
78.4-89.5), 86.9% (95% CI 82.4-90.3) and 86.2% (95% CI 78.4-91.5) respectively. At
Centres 1 and 2, 12/730 (1.6%) and 7/181 (4%) respectively of patients with a benign
microbubble/ CEUS SLN core biopsy had 2 or more lymph node (LN)
macrometastases found at the end of primary surgical treatment.
Conclusions
The identification and biopsy of SLN using CEUS is a reproducible technique.
Advances in knowledge
In the era of axillary conservation, microbubble/ CEUS SLN core biopsy has the
potential to succeed surgical staging of the axilla.
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Dear Reviewers, 
 
Many thanks for your constructive review, which was very welcome. I have now 
addressed your comments. 
 
Reviewer no. 1 
 
1. As suggested, an additional paragraph has been added to the discussion 
and conclusion to emphasise the added value of CEUS and biopsy to a 
normal grey-scale axillary ultrasound with an additional reference. 
2. A recent publication has been referenced with a sentence (in the 
discussion) explaining that a vacuum assisted biopsy does not increase 
the sensitivity of CEUS as a test to identify sentinel node metastases.  
3. The primary data regarding evidence of a core biopsy in surgically excised 
lymph nodes has been obtained and added to the results sections and the 
discussion.  
4. In the discussion section, an explanation has been given on how to avoid 
overtreatment of the axilla if CEUS sentinel node biopsy is adopted into 
routine practice. In the conclusion section more evidence and context has 
been added (including another reference) to justify the proposition that 
microbubble/ CEUS SLN core biopsy has the potential to replace surgical 
staging of the axilla particularly if it is combined with a grey-scale 
ultrasound. 
5. The missing value in figure 3 has been added. 
 
Reviewer no. 2 
 
1. A sentence in the discussion has been added about training. In addition, a 
cost analysis directly comparing surgical sentinel node excision with 
microbubble/ CEUS SLN core biopsy has been added to the conclusion. A 
full economic assessment has not been carried out to look at the cost of 
surgical morbidity following SLNE such as ITU admission if the patient 
develops anaphylaxis to blue dye.  
 
In terms of operating time, a SLNE takes approximately 30 minutes in 
addition to the breast procedure but the patient remains under general 
anaesthesia. Although modern anaesthesia is safe most anaesthetists 
prefer short procedures especially if the patient is obese or has other co-
morbidities so reducing the length by 30 minutes may prove important. 
Also, if 30 minutes can be saved per appropriate patient over the course 
of a full operating day, this may gain enough time for another case to be 
added and improve theatre utilisation. A sentence to this effect has been 
added to the conclusion. 
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Enhanced pre-operative axillary staging using intradermal microbubbles 
and contrast-enhanced ultrasound to detect and biopsy sentinel lymph 
nodes in breast cancer: A potential replacement for axillary surgery 
 
Short title:  Microbubble and CEUS core biopsy of sentinel nodes in breast 
cancer 
 
Abstract 
Objectives 
To compare the experience of 4 UK Centres in the use of intradermal 
microbubbles and contrast enhanced ultrasound (CEUS) to pre-operatively 
identify and biopsy sentinel lymph nodes (SLN) in patients with breast cancer.  
Methods 
In all centres, breast cancer patients had a microbubble/ CEUS SLN core biopsy 
prior to axillary surgery and patients in Centres 1 and 2 had a normal grey-scale 
axillary ultrasound. Data was collected between 2010 and 2016; 1361 from 
Centre 1 (prospective, sequential), 376 from Centre 2 (retrospective, sequential), 
122 from Centre 3 (retrospective, selected) and 48 from Centre 4 (prospective, 
selected).  
Results 
SLN were successfully core biopsied in 80% (Centre 1), 79.6% (Centre 2), 77.5% 
(Centre 3) and 88% (Centre 4). The sensitivities to identify all SLN metastases 
were 46.9% (95% CI 39.4-55.1), 52.5% (95% CI 39.1-65.7), 46.4% (95% CI 27.5-
66.1) and 45.5% (95% CI 16.7-76.6) respectively. Specificities; 99.7% (95% CI 
98.9-100), 98.1% (95% CI 94.5-99.6), 100% (95% CI 93.2-100%) and 96.3% 
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(95% CI 81-99.9) respectively. Negative predictive values; 87.0% (95% CI 84.3-
89.3), 84.5% (95% CI 78.4-89.5), 86.9% (95% CI 82.4-90.3) and 86.2% (95% CI 
78.4-91.5) respectively. At Centres 1 and 2, 12/730 (1.6%) and 7/181 (4%) 
respectively of patients with a benign microbubble/ CEUS SLN core biopsy had 2 
or more lymph node (LN) macrometastases found at the end of primary surgical 
treatment. 
Conclusions 
The identification and biopsy of SLN using CEUS is a reproducible technique.  
Advances in knowledge 
In the era of axillary conservation, microbubble/ CEUS SLN core biopsy has the 
potential to succeed surgical staging of the axilla.  
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Introduction 
Sentinel lymph node excision (SLNE) is the axillary staging method of choice for 
breast cancer patients with normal axillary lymph nodes (LN) on grey-scale 
ultrasound or a benign biopsy of morphologically abnormal LN (1,2). Although 
SLNE has less reported morbidity than axillary lymph node dissection (ALND) it 
remains a surgical procedure performed under general anaesthesia with 
recognised immediate complications such as infection (11%) and long term 
problems with sensory loss (11%) and arm lymphoedema (5%) at 12 months (3) 
The operation is also reliant upon 2 tracers (radioactive isotope and blue dye) to 
locate SLN and maintain a false negative rate of 6% (4). The blue dye carries a 
hazard of anaphylaxis (0.9%) (5) and there are logistical challenges in obtaining 
medical grade radioisotopes.  
Recently, the practice of removing all malignant axillary LN to achieve local 
control has been challenged by the results of a trial where patients with SLN 
metastases were randomized to a completion ALND or no further axillary 
surgery (6). The local recurrence rate in the axilla was low with no difference 
between the groups despite the fact that 27.3% of patients in the ALND arm had 
further lymph node metastases retrieved  (6). These results emphasize the role 
of modern adjuvant treatment in preventing loco-regional disease recurrence 
and have led to the introduction of conservative surgical management of the 
axilla for patients with up to 2 SLN macrometastases (7). 
In patients with breast cancer, SLN can be identified and percutaneously 
biopsied in the clinic using intradermally injected microbubbles and contrast-
enhanced ultrasound (CEUS) (8, 9, 10). The technique was originally described in 
a swine melanoma model (11) and following a trial period, was incorporated 
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into routine practice at Centre 1 for all invasive breast cancer patients with a 
normal grey-scale axillary ultrasound (12,13) to aid treatment planning such as 
the selection of appropriate axillary surgery (14), the initiation of neo-adjuvant 
systemic therapy (15) and reconstructive decisions for patients who may 
consequently benefit from post-mastectomy radiotherapy (16). The 
identification of SLN using microbubbles and CEUS was previously validated 
against the surgical detection of SLN using blue dye and radioisotope and 
concordance was found in 93% of cases that had a core biopsy (13). Other 
Centres in the UK also adopted the microbubble/ CEUS SLN biopsy technique for 
use in their own practice. 
Previous work from Centre 1 has shown that patients with invasive breast 
cancer and a normal grey-scale ultrasound and benign microbubble/ CEUS SLN 
core biopsy are unlikely to have extensive metastatic axillary disease that is both 
grey-scale ultrasound occult and missed on SLN core biopsy (14). These results 
suggest that complete radiological staging of the axilla might be feasible.  
We therefore aimed to assess the reproducibility of the microbubble/ CEUS SLN 
core biopsy procedure by comparing the test accuracy of Centre 1 with a smaller 
population of consecutive patients from Centre 2 as well as 2 other UK centres 
using patients, which were selected on the basis of tumour clinico-pathological 
features.  We also examined the technical performance of individual radiologists 
at Centre 1. Lastly, we measured the volume of axillary metastases in patients 
from Centres 1 and 2 to determine the proportion of patients with a false 
negative microbubble/ CEUS SLN core biopsy who had 2 or more axillary LN 
macrometastases at the end of primary surgical treatment.  
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Methods 
Study Design 
Data was collected from 4 Breast Units across the UK (figure 1). In Centres 1 and 
2, patients were included with newly diagnosed breast cancer and an initial grey-
scale axillary ultrasound +/- biopsy of indeterminate/ abnormal LN (17) and 
only those with normal axillary imaging/ benign pathology proceeded to have a 
microbubble/ CEUS SLN core biopsy. At Centre 3, patients with newly diagnosed 
grade 2 or 3 invasive breast cancer and a normal grey-scale axillary ultrasound 
or indeterminate LN that were inadequate (not enough cells to make a diagnosis) 
or benign on cytology were included. At Centre 4, patients with newly diagnosed 
T2 or larger tumours, grade 2 or 3 invasive breast cancer with grey-scale 
ultrasound indeterminate axillary LN were included. Centres 3 and 4 selected 
patients at the discretion of the multi-disciplinary team. In all centres, pregnant 
patients and those with locally advanced/ metastatic disease were excluded. At 
Centre 1, 1361 consecutive patients were identified from a prospective database 
of patients having microbubble/ CEUS guided SLN core biopsy between 
December 2010 and November 2016. A proportion of this data (570 patients) 
has been previously analysed and published (14). Retrospective data was 
collected on 376 consecutive patients from Centre 2 between July 2010 and July 
2014. Retrospective data was collected on 122 selected patients from Centre 3 
between July 2013 and December 2015. Prospective data was collected on 48 
selected patients from Centre 4 between June 2013 and February 2015.  
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Identification and biopsy of SLN using intradermal microbubbles and CEUS 
Following a diagnosis of breast cancer, patients had an injection of ultrasound 
contrast agent (Sonovue, BRACCO Imaging S.p.A, Italy). 0.2ml of ultrasound 
contrast agent was injected intra-dermally in the periareolar, upper outer 
quadrant position using a 26G needle with a 1 ml tuberculin syringe at Centre 1, 
Centre 2 and Centre 3. Centre 4 used a 24G needle with a 1 ml tuberculin syringe.  
Lymphatic channels were visualised on contrast pulse sequencing and tracked 
into the axilla. Areas of contrast accumulation were also imaged with grey scale 
or live dual images (figure 2). Further injections of contrast up to 1ml and 3 
consecutive injections together with injection site massage for 10-30 seconds 
were performed if progress of contrast through the lymphatic vessels was slow/ 
not immediately evident. Once identified, the SLN was biopsied using a core 
biopsy technique, Centres 1 and 2 (Achieve automatic biopsy device, Carefusion, 
San Diego, California, USA. 2-3x 14-16G), Centre 3 (Trucut biopsy device, San 
Diego, California, USA. 3-4x 14G) and Centre 4 (Trucut biopsy device. 3-4x 18G).  
Microbubble/ CEUS guided SLN core biopsies were performed by consultant 
breast radiologists; 7 at Centre 1, 4 at Centre 2, 2 at Centre 3 and a single 
consultant breast radiologist at Centre 4. Three of the 7 radiologists at Centre 1 
also worked at Centre 2. Very rarely 2 SLN were visualised and both were 
biopsied at Centre 1, Centre 2 and Centre 3. At Centre 4, only the first enhancing 
SLN was biopsied. Centre 1 ultrasound examinations were performed with a 
Sequoia 512 Acuson (Siemens Medical Systems, Issaquah, Wash, USA) or LOGIQ 
9 (GE Healthcare, Fairfield, CT, USA) using a linear transducer operating at 4.5 to 
15MHz. Centre 2 ultrasound examinations were performed with a LOGIQ 9 using 
a linear transducer operating at 4.5 to 15MHz, Centre 3 ultrasound examinations 
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were performed with a Siemens Antaris or Acuson S1000 (Siemens Medical 
Systems, Issaquah, Wash, USA) and Centre 4 ultrasound examinations were 
performed with a Toshiba Aplio 500 (Toshiba Medical Systems Europe B.V., 
Zilverstraat 1, 2718RP, Zoetermeer, The Netherlands) using a mid-range linear 
probe (PLT-704SBT Linear). All ultrasound machines provided: conventional 
grey-scale, pulse-inversion harmonic grey scale, contrast specific sonographic 
imaging with live dual images of tissue only and contrast agent images. In order 
to reduce microbubble destruction, low mechanical index values were applied 
(MI: 0.1-0.4). Each centre performed histological analysis on biopsy samples. 
Centres 1 and 2 also used pancytokeratin (MNF116) immunohistochemical 
staining for patients with a lobular phenotype.  
 
Surgical Management of the axilla 
Initially, at Centre 1 and Centre 2 if the microbubble/ CEUS SLN core biopsy 
contained malignant cells, patients were advised to have an ipsilateral ALND. 
Later in the study period (Centre 1 and Centre 2) and throughout the study 
period at Centre 3 and Centre 4, to avoid surgical overtreatment, patients were 
recommended to have ALND only if a macrometastasis (>2mm) was seen in the 
core biopsy specimen and those with core biopsy isolated tumour cells (ITC) or 
micrometastases (<2mm) had SLNE.  Patients also had SLNE if the core biopsy 
identified indeterminate cellular changes, normal lymphoid tissue, inadequate 
tissue sampling or the patient declined primary ALND. Before surgery, patients 
had an injection of radioactive isotope (Nanocoll, G.E Healthcare, Chicago, USA), 
between 20 and 40mbeq in the peri-areolar, upper outer quadrant position. 
Later that day or the following day, patients underwent surgical resection.  After 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  8 
anaesthetic induction, patients received a 2ml injection of blue dye (Bleu Patente 
V 2.5%, Guerbet, France) sub-dermally in the periareolar, upper outer quadrant 
position. A gamma probe (Navigator GPS, RMD Instruments, Watertown, USA) 
was used to identify SLN. All SLN within the axilla were excised and sent for local 
histological analysis including immunohistochemical staining for patients with a 
lobular phenotype at Centres 1 and 2. The total volume of axillary metastases at 
the end of surgical treatment was determined for each patient using the 
following scoring system: 1 (LN containing a macrometastasis), 0.5 (LN 
containing a micrometastasis) and 0.2 (LN containing isolated tumour cells)(12).  
 
Statistics 
The proportion of patients who had SLN identified was calculated. Using 
contingency tables, the sensitivity and specificity of a successful (LN tissue 
retrieved) CEUS guided SLN core biopsy, as the index test to identify SLN 
metastases in breast cancer patients with invasive disease was determined with 
axillary surgery (SLNE/ ALND) as the reference standard. The estimated values 
were calculated along with corresponding 95% confidence intervals (CI) 
illustrating the uncertainty in the results. All CI were calculated using the exact 
binomial method. The prevalence of SLN metastases in each population was 
derived from the reference standard. For centres 1 and 2, positive and negative 
predictive values were calculated directly, as they both employed consecutive 
enrolment so the study prevalence will be representative of the population of 
interest. For centres 3 and 4, which only included a non-randomly selected 
subset of eligible patients, Bayesian methods were used to calculate positive and 
negative predictive values, using the prevalence from centre 1 (the largest centre 
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with consecutive enrolment). The Mann-Whitney test was used to compare the 
volume of axillary metastases between patients with a false negative and true 
positive microbubble/ CEUS SLN biopsy. All analysis was completed using Stata 
software (Stata version 13.1; Stata Corp LP, College Station, Tx, USA). 
 
Ethics 
Kent Research Ethics Committee, UK approved the original trials at 
Centre 1 (reference numbers: 04/Q1801/25 and 11/H1101/1) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA) sanctioned the 
use of microbubbles by intraparenchymal injection (Eudract Number: 2004-
002423-41). All participating Centres were NHS Trusts and the New Procedures 
Committees at Centre 1, Centre 2, and Centre 3 and the Breast Services 
Committee at Centre 4 each approved the use of intradermal microbubbles and 
CEUS to identify and biopsy SLN in patients with breast cancer at their 
institution. 
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Results 
Visualisation and targeted core biopsy of SLN using intradermal 
microbubbles and CEUS  
A total of 1361 consecutive patients were identified from a prospectively 
maintained database at Centre 1. Complete data was not available for 12 patients 
and 1 patient had a fine needle aspiration biopsy (FNAB) rather than a core 
biopsy. Sentinel lymph nodes were clearly visualised by CEUS in 1216 of the 
1348 patients (90%). In the 132 cases where the intradermally injected 
microbubbles failed to traffic through lymphatics to identify SLN, 25 (19%) had 
previous surgery on the breast/ axilla, a post breast biopsy haematoma or 
malignant involvement of the nipple areolar complex.  A successful SLN core 
biopsy was achieved in 1083 of the 1348 patients (80%). The performance 
statistics of the 7 Centre 1 radiologists are presented in Table 1.  
A total of 376 patients were identified retrospectively at Centre 2. Complete data 
was not available for 15 patients, 3 patients had a FNAB and 15 patients did not 
have the microbubbles/ CEUS procedure. Sentinel lymph nodes were clearly 
visualised by CEUS in 290 of 343 patients (84.5%). A successful core biopsy of 
SLN was achieved in 273 of 343 patients (79.6%). 
At Centre 3, 121 patients were identified retrospectively. Complete data was not 
available for one patient. Sentinel lymph nodes were clearly visualised by CEUS 
in 109 of the 120 patients (90.8%). A successful core biopsy of SLN was achieved 
in 93 of 120 patients (77.5%). Prospective data was collected on 48 patients at 
Centre 4. There were technical problems with the initial 5 patients, as the 
lymphatics could not be visualised. However, once the settings on the ultrasound 
machine were optimised, SLN were clearly visualised and successfully core 
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biopsied in 38 of 43 patients (88%).  In all centres, there were no allergic 
reactions following the administration of contrast agent and only one significant 
bleeding complication (Centre 1) of a large haematoma after SLN core biopsy 
which was evacuated 2 weeks later at the time of primary surgical treatment. 
 
Identification of SLN metastases in patients with invasive breast cancer and 
a successful microbubble/ CEUS SLN core biopsy that underwent primary 
surgical treatment  
In patients with a successful microbubble/ CEUS SLN core biopsy, the following 
were excluded from final analysis; those with pre-invasive disease (DCIS), those 
who had primary systemic or endocrine therapy and patients who did not 
proceed with axillary surgery because of choice or inability to tolerate a general 
anaesthetic. At Centres 1 and 2, patients with un-biopsied grey-scale abnormal 
LN were excluded and 6 patients at Centre 1 were also excluded because of 
incomplete surgical data.  
At Centre 1, 816 of the 1083 patients with a successful microbubble/ CEUS SLN 
core biopsy went on to have primary surgical treatment. Evidence of a core 
biopsy tract was seen in the excised SLN of 656 (80%) patients, 127 (16%) 
patients did not have a core biopsy tract visualized in excised SLN, 2 (0.2%) 
patients had a core biopsy tract seen in non-SLN and data regarding the presence 
of a core biopsy tract was not recorded for 31 (3.8%) patients.  For the other 
centres; 215 of 273 patients (Centre 2), 80 of 93 patients (Centre 3) and 38 of 38 
patients (Centre 4) with a successful microbubble/ CEUS SLN core biopsy went 
on to have primary surgical treatment. Comprehensive data documenting 
evidence of previous biopsy in excised SLN was not available for Centres 2, 3 and 
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4. For each centre, the accuracy of a successful microbubble/ CEUS SLN core 
biopsy to identify SLN metastases in patients with invasive breast cancer is 
presented in Table 2. 
 
Volume of axillary metastases at the end of primary surgical treatment in 
patients with invasive breast cancer, radiologically normal axillary LN and 
a successful microbubble/ CEUS SLN core biopsy in Centres 1 and 2 
At Centre 1, 95 patients had a false negative microbubble/ CEUS SLN core biopsy 
with metastases found in the excised SLN. Of these, evidence of a core biopsy 
tract was seen in the excised SLN of 69 (72.6%) patients, 23 (24.2%) patients did 
not have a core biopsy tract visualised in excised SLN and data regarding the 
presence of a core biopsy tract was not recorded for 3 (3.2%) patients.    Sixty-
one patients (64%) with a false negative microbubble/ CEUS SLN core biopsy 
result went on to have a completion ALND and 34 (36%) had no further axillary 
surgery (axillary conservation). At the end of primary surgical treatment, 12 
patients (12.6%) were found to have 2 or more LN macrometastases and 82 
patients (87.4%) had less than 2 LN macrometastases. Of the 730 patients with 
an initial benign microbubble/ CEUS SLN core biopsy, only 12 (1.6%) had 2 or 
more LN macrometastases found at the end of primary surgical treatment (Table 
3). Eighty-four patients at Centre 1 had a true positive microbubble/ CEUS SLN 
core biopsy and 81 (96%) had an ALND whereas 3 (4%) had a SLNE. Of these 84 
patients, 42 (50%) had 2 or more axillary LN macrometastases at the end of 
primary surgical treatment.  
At Centre 2, 28 patients had a false negative microbubble/ CEUS SLN core biopsy 
with metastases found in the excised SLN. Nineteen patients (68%) went on to 
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have a completion ALND and 9 (32%) had axillary conservation. At the end of 
primary surgical treatment, 7 patients (25%) were found to have 2 or more 
axillary macrometastases and 22 patients (75%) had a malignant axillary LN 
score less than 2 or had ITC in multiple LN (one patient with ITC in 13 LN). Of the 
181 patients with an initial benign microbubble/ CEUS SLN core biopsy, 7 (4%) 
had 2 or more axillary macrometastases found at the end of primary surgical 
treatment (Table 4). Thirty-one patients at Centre 2 had a true positive 
microbubble/ CEUS SLN core biopsy and 30 (97%) had an ALND whereas 1 (3%) 
had a SLNE. Of these 31 patients, 14 (45%) had 2 or more axillary LN 
macrometastases at the end of primary surgical treatment.  
For both centres, at the end of surgical treatment the difference between the 
final malignant LN score of false negative versus true positive microbubble/ 
CEUS SLN core biopsies was statistically significant (figure 3). 
 
Discussion 
Despite the use of different ultrasound machines and variations in the methods 
and patient selection, the identification and core biopsy of SLN using intradermal 
microbubbles and CEUS in patients with breast cancer is a reproducible 
technique across multiple centres. Overall, the visualisation of SLN across the 4 
centres ranged from 84.5% to 90.8% and a successful core biopsy from 77.5% to 
88%. Factors that appeared to adversely affect the visualisation of SLN at Centre 
1 included previous surgery and disease involvement of the nipple areolar 
complex.  
There is undoubtedly a learning curve associated with the procedure and 
familiarity with the equipment is important as demonstrated by the data from 
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Centre 4 where they experienced technical problems with the first 5 patients. 
The performance of Centre 1 radiologists also highlight the distinct 
competencies of the 2 components of the procedure, namely SLN identification 
and SLN core biopsy. Even though identical ultrasound equipment and methods 
were used, the percentage of procedures with successful visualisation of SLN 
varied from 97% to 73%, which suggests either that not all radiologists at Centre 
1 received adequate procedural training before performing the test or some 
found it difficult to visualise microbubbles trafficking through lymphatic 
channels. Six of the 7 radiologists were fairly consistent in their ability to 
successfully core biopsy visualised SLN, but 1 obviously struggled and only 
successfully retrieved lymphoid tissue in 70% of cases. Anecdotally, most 
radiologists accustomed to the procedure recommend that novices observe 3 
cases, then perform 10 cases supervised before undertaking 30 independent 
procedures with an audit of their results. Once proficient, the whole procedural 
time is 15 to 30 minutes. 
There is scope to improve the technology of CEUS.  In swine models, LN 
metastases can be identified as areas devoid of contrast agent (11) and in a 
recent study of breast cancer patients, the sensitivity of CEUS as a test to identify 
SLN metastases using only enhancement patterns (no biopsy) was 81.8% (18). 
Innovations such as ultrafast ultrasound (19), super resolution imaging (20) and 
improved lymphatic microbubble transit (21) may improve the ability of 
clinicians to visualise SLN and achieve a reliable standard. 
The sensitivity of a microbubble/ CEUS core biopsy as a test to identify SLN 
metastases in patients with invasive breast cancer and a normal grey-scale 
axillary ultrasound/ benign axillary LN biopsy is consistently around 50% with 
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Centres 2, 3 and 4 within the 95% confidence intervals of Centre 1. As grey-scale 
axillary ultrasound can usefully identify approximately 50% of LN metastases 
(22), the addition of a microbubble/ CEUS SLN core biopsy substantially 
increases the overall detection rate for metastatic axillary LN. Consequently, the 
negative predictive value of the test is high and <5% of patients (Centres 1 and 
2) with a normal grey-scale ultrasound and benign microbubble/ CEUS SLN core 
biopsy had 2 or more LN macrometastases detected by axillary surgery. 
We have previously speculated that the technique has a high false negative rate 
because the core biopsy fails to pick up small metastatic deposits in SLN (13) and 
this may be the reason why very few patients with a false negative microbubble/ 
CEUS core biopsy at Centres 1 and 2 had two or more axillary LN 
macrometastases found at the end of primary surgical treatment. Yet, retrieving 
more LN tissue with a vacuum-assisted biopsy technique does not appear to 
appreciably increase the sensitivity of microbubbles and CEUS (23). 
 Alternatively, it is usual for only one SLN to be visualised and biopsied with 
CEUS but the median number of SLN retrieved with a surgical excision is 2 (3). In 
this series, 80% of surgically excised LN at Centre 1 showed evidence of a 
previous core biopsy and this proportion dropped to 72.6% in patients with a 
false negative benign microbubble/ CEUS SLN core biopsy. This raises the 
possibility that in the false negative cases, the second or subsequent SLN 
contained the metastases and perhaps more than one SLN should be actively 
sought with the microbubbles/ CEUS procedure. 
When compared to Centre 1, a higher proportion of Centre 2 patients with a 
benign microbubble/ CEUS SLN core biopsy had two or more axillary 
macrometastases found at the end of surgical treatment (1.8 vs 4%).  This may 
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be related to the smaller patient sample size in Centre 2 or the higher prevalence 
of LN metastases in patients with a successful microbubble/ CEUS SLN core 
biopsy in Centre 2 (27% vs 22% at Centre 1). As the patient and 
clinicopathologic features of the tumours were similar in both centres, the 
greater prevalence of LN metastases at Centre 2 may be a consequence of a 
lower initial metastatic LN detection rate with grey-scale axillary ultrasound.  
The difference in the volume of axillary disease between patients with a false 
negative and true positive microbubble/ CEUS SLN core biopsy at the end of 
primary surgical treatment was statistically significant in Centres 1 and 2. When 
compared to the false negative groups in Centres 1 and 2, more patients with a 
true positive microbubble/ CEUS SLN core biopsy had complete axillary surgery 
(ALND) rather than axillary conservation (SLNE). The retrieval of a greater 
number of LN in the true positive groups from Centres 1 and 2 may therefore 
have increased the total number of axillary LN metastases found at the end of 
surgical treatment and influenced the final metastatic score. However, in a 
previous publication from Centre 1 (14) comparing only patients with complete 
axillary surgery (ALND), the difference in the volume of axillary disease between 
those with a false negative and true positive microbubble/ CEUS SLN core biopsy 
remained stastically significant. 
An argument against using CEUS to biopsy SLN in routine practice is that 
patients with a biopsy containing malignant cells are committed to a primary 
ALND for what may be a low burden of axillary disease. This can be mitigated 
against by offering SLNE to patients with micrometastases in the core biopsy 
specimen. It should also be noted that 50% of patients at Centre 1 and 45% of 
patients at Centre 2 with a true positive microbubble/ CEUS SLN core biopsy had 
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2 or more axillary macrometastases found at the end of surgical treatment and 
therefore using the test for patients who are not eligible for axillary conservation 
(7) is beneficial.  
Conclusion 
The results of the American College of Surgeons Oncology Group Z0011 trial (6) 
have changed practice by showing that loco-regional control of axillary 
metastases is not solely dependant upon surgical excision and residual disease 
can be treated with adjuvant therapy. In addition, anatomic staging of breast 
cancer is likely to become less relevant to treatment decisions as tumour 
genomic and molecular assays are better understood (24). Based on recent 
information obtained from Centre 1, a SLNE costs 3.6x the cost of a microbubble/ 
CEUS SLN core biopsy (£671.63 vs £189 respectively). Omitting axillary surgery 
will improve theatre utilisation (potentially allowing more cases to be added to a 
list) as well as reducing the anaesthetic time for each patient. In the era of 
axillary conservation, molecular medicine and dwindling resources the 
combination of grey-scale axillary ultrasound and microbubble/ CEUS SLN core 
biopsy has the potential to succeed surgical staging of the axilla. Further work 
now needs to be undertaken to refine the procedure with protocols, standard 
setting and training. 
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Figure Captions 
Figure 1 
Diagram showing the selection and flow of participants from each centre 
through the study. Lymph node (LN), Sentinel Lymph Node (SLN), 
Contrast enhanced ultrasound (CEUS), Ductal Carcinoma in situ (DCIS), 
isolated tumour cells (ITC), surgical sentinel lymph node biopsy (SLNB), 
axillary lymph node dissection (ALND) and POSNOC – (POsitive Sentinel 
NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or 
axillary radiotherapy. A randomised controlled trial of axillary treatment 
in women with early stage breast cancer who have metastases in one or 
two sentinel nodes). 
 
Figure 2 
A. Ultrasound contrast pulse sequencing image of a SLN (white arrow) 
after injection of intradermal microbubbles (between 0.2 and 1 ml 
injected using a 26G needle with 1ml tuberculin syringe) into the UOQ 
periareolar area of the breast. B. Grey scale ultrasound image of the same 
SLN as visualised in A. Images provided by Centre 3. 
 
Figure 3 
A. Volume of axillary disease at the end of primary surgical treatment for 
individual patients at Centres 1 and 2 who had a false negative (FN) or 
true positive (TP) microbubble/ CEUS core biopsy of SLN. Axillary lymph 
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node dissection (ALND) and sentinel lymph node excision (SLNE). B. The 
total volume of axillary metastases at the end of surgical treatment was 
determined using a scoring system (isolated tumour cells = 0.2, each LN 
micrometastasis = 0.5 and each LN macrometastasis = 1). The Mann-
Whitney test was used to compare the volume of axillary metastases 
between patients with a false negative and true positive microbubble/ 
CEUS SLN biopsy in both centres.  
 
Table 1 
Performance statistics of 7 consultant breast radiologists at Centre 1 
(Total 1349 of 1361 procedures). In 12 cases the data was incomplete and 
the name of the radiologist was not recorded. For radiologist no.1, one 
successful procedure was a fine needle aspiration biopsy rather than a 
core biopsy. 
 
Table 2 
Test accuracy of CEUS guided SLN biopsy using intradermally injected 
microbubbles in women with normal (centres 1 and 2) or indeterminate 
results from previous grey scale ultrasound (with or without previous 
biopsy). Reference standard is Sentinel Lymph node excision (SLNE) or 
axillary lymph node dissection (ALND). Positive predictive value (PPV) 
and negative predictive value (NPV) were calculated directly for centres 1 
and 2 who employed consecutive recruitment, and using Bayesian 
methods with 22% prevalence at centres 3 and 4 as these were not a 
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consecutively or randomly selected group. True positive (TP), false 
positive (FP), true negative (TN) and false negative (FN). 
 
Table 3 
Age and clinicopathological characteristics of all patients at Centre 1 (first 
column) with a successful microbubble/CEUS SLN core biopsy before 
primary surgical treatment and Centre 1 patients with false negative 
microbubble/ CEUS SLN core biopsies sub-divided into micrometastases 
(<2mm)/ isolated tumour cells (ITC), low volume metastases and high 
volume metastases identified at the end of primary surgical treatment. 
Data are expressed as n (%). Estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (Her2), 
invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC). 
 
Table 4 
Age and clinicopathological characteristics of all patients at Centre 2 (first 
column) with a successful microbubble/CEUS SLN core biopsy before 
primary surgical treatment and Centre 2 patients with false negative 
microbubble/ CEUS SLN core biopsies sub-divided into micrometastases 
(<2mm)/ isolated tumour cells (ITC), low volume metastases and high 
volume metastases identified at the end of primary surgical treatment. 
Data are expressed as n (%). Estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (Her2), 
invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC). 
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Table 1 
 Centre 1 – Consultant Breast Radiologists 
 
1 2 3 4 5 6 7 
 
Total Procedures 
 
276 
 
37 
 
501 
 
81 
 
116 
 
207 
 
131 
Procedures where core biopsy 
not attempted 
 
0 
(0%) 
 
 
0 
(0%) 
 
 
0 
(0%) 
 
 
2 
(2 .5%) 
 
 
0 
(0 %) 
 
 
0 
(0 %) 
 
 
1 
(0.8%) 
 
 
Procedures with successful 
visualisation of SLN 
 
 
269 
(97.5%) 
 
 
 
33 
(89.2%) 
 
 
 
457 
(91.2%) 
 
 
 
59 
(72.8%) 
 
 
 
94 
(81%) 
 
 
 
187 
(90.3%) 
 
 
 
118 
(90.1%) 
 
 
Procedures without SLN tissue 
retrieved 
 
 
1 
(0.4%) 
 
 
 
1 
(2.7%) 
 
 
 
64 
(12.8%) 
 
 
 
2 
(2.5%) 
 
 
 
10 
(8.6%) 
 
 
 
18 
(8.7%) 
 
 
 
34 
(26%) 
 
 
Successful retrieval of lymphoid 
tissue in those with visualised 
SLN 
 
 
268 
(99.6%) 
 
 
 
32 
(97%) 
 
 
 
393 
(86%) 
 
 
 
57 
(96.6%) 
 
 
 
84 
(89.4%) 
 
 
 
169 
(90.4%) 
 
 
 
84 
(71.2%) 
 
 
Total successful visualisation and 
core biopsy of SLN 
l  
268 
(97.1%) 
 
32 
(86.5%) 
 
393 
(78.4%) 
 
57 
(70.4%) 
 
 
84 
(72.4%) 
 
 
169 
(81.6%) 
 
 
84 
(64.1%) 
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Table 2 
Centre 
 
 
Prevalence 
of LN 
metastases 
TP FP TN FN Sensitivity Specificity PPV NPV 
 
1 
 
22% 
 
84 
 
2 
 
635 
 
95 
 
46.9% 
(39.4-55.5%) 
 
 
99.7 % 
(98.95-100%) 
 
 
97.7% 
(91.9-99.7%) 
 
87.0% 
(84.3-89.3% 
2 27% 31 3 153 28 
 
52.5%  
(39.1-65.7%) 
 
 
98.1% 
(94.5-99.6%)  
 
 
91.2% 
(76.3-98.1%)  
 
 
84.5%  
(78.4-89.5%) 
 
3 35% 13 0 52 15 
 
46.4% 
(27.5-66.1%)  
 
 
100%  
(93.2-100%) 
 
 
100%  
(75.3-100%) 
 
 
86.9% 
(82.4-90.3%)  
 
4 29% 5 1 26 6 
 
45.5% 
(16.7-76.6%)  
 
 
96.3%  
(81.0-99.9%) 
 
 
77.6%  
(31.3-96.3%) 
 
 
86.2 % 
(78.4 -91.5%) 
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Table 3 
  
Volume of disease at the end of surgical treatment (microbubble/ CEUS false negative core 
biopsy) 
  
Centre 1  All Patients 
Micrometastasis/ 
ITC 
Low (<2 LN macrometastases) High (2 or more LN macrometastases) 
          
Total number of patients 816 37 46 12 
     
  
15 (41%) ALND 34 (74%) ALND 12 (100%) ALND 
     Median age in years 
(range) 
61 (30-94) 61 (42-89) 55 (32-90) 53 (36-69) 
     
Receptor Status 
    
ER positive 707 (87%) 32 (86%) 40 (87%) 11 (92%) 
ER unknown 4 (0.4%) 0 0 0 
Her-2 positive 79 (10%) 3 (8%) 2 (4%) 1 (8%) 
Her-2 not recorded 13 (1.6%) 0 2 (4%) 0 
ER-/PR-/Her-2- 72 (10%) 4 (10.8%) 4 (9%) 0 
ER-/PR-/HER-2+ 28 (3%) 1 (2.7%) 1 (2%) 1 (8%) 
     
Invasive Tumour Size 
    
DCIS + microinvasion 5 (0.6%) 0 0 0 
T1 472 (58%) 19 (51%) 17 (37%) 4 (33%) 
T2 199 (24%) 10 (27%) 18 (39%) 5 (42%) 
T3 29 (4%) 5 (14%) 3 (7%) 1 (8%) 
Multifocal 111 (14%) 3 (8%) 8 (17%) 2 (17%) 
Unknown 0 0 0 0 
     
Tumour Grade 
    
Grade 1 180 (22%) 6 (16%) 7 (15%) 4 (33%) 
Grade 2 392 (48%) 20 (54%) 21 (46%) 6 (50%) 
Grade 3 209 (26%) 11 (30%) 14 (30%) 1 (8%) 
Mixed grade 29 (4%) 0 4 (9%) 1 (8%) 
Unknown 1 (0.1%) 0 0 0 
     
Tumour Type 
    
IDC 660 (81%) 23 (62%) 38 (83%) 11 (92%) 
ILC 103 (13%) 11 (30%) 6 (13%) 1 (8%) 
Other 29 (4%) 1 (3%) 1 (2%) 0 
Mixed 17 (2%) 2 (5%) 1 (2%) 0 
Unknown 2 (0.2%) 0 0 0 
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Table 4 
  Volume of disease at the end of surgical treatment (microbubble/ CEUS false negative core biopsy) 
  
Centre 2 All Patients 
Micrometastasis/ 
ITC 
Low (<2 LN macrometastases) High (2 or more LN macrometastases) 
     
Total number of patients 215 10 11 7 
     
  
2 (20%) ALND 10 (91%) ALND 7 (100%) ALND 
     Median age in years 
(range) 
64 (31-93) 63.5 (37-93) 62 (38-91) 55 (47-72) 
     
Receptor Status 
    
ER positive 176 (82%) 10 (100%) 8 (73%) 6 (86%) 
ER unknown 6 (3%) 0 1 (9%) 1 (14%) 
Her-2 positive 29 (13%) 1 (10%) 0 1 (14%) 
Her-2 not recorded 8 (4%) 0 1 (9%) 1 (14%) 
ER-/PR-/Her-2- 23 (11%) 0 1 (9%) 0 
ER-/PR-/HER-2+ 10 (5%) 0 0 0 
     
Invasive Tumour Size 
    
DCIS + microinvasion 0 0 0 0 
T1 118 (55%) 2 (20%) 6 (55%) 2 (29%) 
T2 71 (33%) 6 (60%) 4 (36%) 5 (71%) 
T3 9 (4%) 0 0 0 
Multifocal 17 (8%) 2 (20%) 0 0 
Unknown 0 0 1 (9%) 0 
     
Tumour Grade 
    
Grade 1 35(16%) 1 (10%) 0 2 (29%) 
Grade 2 102 (47%) 6 (60%) 5 (45.5%) 1 (14%) 
Grade 3 68 (32%) 2 (20%) 4 (36%) 4 (57%) 
Mixed grade 4 (2%) 0 0 0 
Unknown 6 (3%) 0 2 (18%) 0 
     
Tumour Type 
    
IDC 160 (74%) 7 (70%) 8 (73%) 5 (71%) 
ILC 24 (11%) 2 (20%) 1 (9%) 0 
Other 16 (7%) 0 0 0 
Mixed 13 (6%) 1 (10%) 1 (9%) 2 (29%) 
Unknown 2 (1%) 0 1 (9%) 0 
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Enhanced pre-operative axillary staging using intradermal microbubbles 
and contrast-enhanced ultrasound to detect and biopsy sentinel lymph 
nodes in breast cancer: A potential replacement for axillary surgery 
 
Short title:  Microbubble and CEUS core biopsy of sentinel nodes in breast 
cancer 
 
Abstract 
Objectives 
To compare the experience of 4 UK Centres in the use of intradermal 
microbubbles and contrast enhanced ultrasound (CEUS) to pre-operatively 
identify and biopsy sentinel lymph nodes (SLN) in patients with breast cancer.  
Methods 
In all centres, breast cancer patients had a microbubble/ CEUS SLN core biopsy 
prior to axillary surgery and patients in Centres 1 and 2 had a normal grey-scale 
axillary ultrasound. Data was collected between 2010 and 2016; 1361 from 
Centre 1 (prospective, sequential), 376 from Centre 2 (retrospective, sequential), 
122 from Centre 3 (retrospective, selected) and 48 from Centre 4 (prospective, 
selected).  
Results 
SLN were successfully core biopsied in 80% (Centre 1), 79.6% (Centre 2), 77.5% 
(Centre 3) and 88% (Centre 4). The sensitivities to identify all SLN metastases 
were 46.9% (95% CI 39.4-55.1), 52.5% (95% CI 39.1-65.7), 46.4% (95% CI 27.5-
66.1) and 45.5% (95% CI 16.7-76.6) respectively. Specificities; 99.7% (95% CI 
98.9-100), 98.1% (95% CI 94.5-99.6), 100% (95% CI 93.2-100%) and 96.3% 
Revised Manuscript - Changes marked
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(95% CI 81-99.9) respectively. Negative predictive values; 87.0% (95% CI 84.3-
89.3), 84.5% (95% CI 78.4-89.5), 86.9% (95% CI 82.4-90.3) and 86.2% (95% CI 
78.4-91.5) respectively. At Centres 1 and 2, 12/730 (1.6%) and 7/181 (4%) 
respectively of patients with a benign microbubble/ CEUS SLN core biopsy had 2 
or more lymph node (LN) macrometastases found at the end of primary surgical 
treatment. 
Conclusions 
The identification and biopsy of SLN using CEUS is a reproducible technique.  
Advances in knowledge 
In the era of axillary conservation, microbubble/ CEUS SLN core biopsy has the 
potential to succeed surgical staging of the axilla.  
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Introduction 
Sentinel lymph node excision (SLNE) is the axillary staging method of choice for 
breast cancer patients with normal axillary lymph nodes (LN) on grey-scale 
ultrasound or a benign biopsy of morphologically abnormal LN (1,2). Although 
SLNE has less reported morbidity than axillary lymph node dissection (ALND) it 
remains a surgical procedure performed under general anaesthesia with 
recognised immediate complications such as infection (11%) and long term 
problems with sensory loss (11%) and arm lymphoedema (5%) at 12 months (3) 
The operation is also reliant upon 2 tracers (radioactive isotope and blue dye) to 
locate SLN and maintain a false negative rate of 6% (4). The blue dye carries a 
hazard of anaphylaxis (0.9%) (5) and there are logistical challenges in obtaining 
medical grade radioisotopes.  
Recently, the practice of removing all malignant axillary LN to achieve local 
control has been challenged by the results of a trial where patients with SLN 
metastases were randomized to a completion ALND or no further axillary 
surgery (6). The local recurrence rate in the axilla was low with no difference 
between the groups despite the fact that 27.3% of patients in the ALND arm had 
further lymph node metastases retrieved  (6). These results emphasize the role 
of modern adjuvant treatment in preventing loco-regionalal disease recurrence 
and have led to the introduction of conservative surgical management of the 
axilla for patients with up to 2 SLN macrometastases (7). 
In patients with breast cancer, SLN can be identified and percutaneously 
biopsied in the clinic using intradermally injected microbubbles and contrast-
enhanced ultrasound (CEUS) (8, 9, 10). The technique was originally described in 
a swine melanoma model (11) and following a trial period, was incorporated 
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into routine practice at Centre 1 for all invasive breast cancer patients with a 
normal grey-scale axillary ultrasound (12,13) to aid treatment planning such as 
the selection of appropriate axillary surgery (14), the initiation of neo-adjuvant 
systemic therapy (15) and reconstructive decisions for patients who may 
consequently benefit from post-mastectomy radiotherapy (16). The 
identification of SLN using microbubbles and CEUS was previously validated 
against the surgical detection of SLN using blue dye and radioisotope and 
concordance was found in 93% of cases that had a core biopsy (13). Other 
Centres in the UK also adopted the microbubble/ CEUS SLN biopsy technique for 
use in their own practice. 
Previous work from Centre 1 has shown that patients with invasive breast 
cancer and a normal grey-scale ultrasound and benign microbubble/ CEUS SLN 
core biopsy are unlikely to have extensive metastatic axillary disease that is both 
grey-scale ultrasound occult and missed on SLN core biopsy (14). These results 
suggest that complete radiological staging of the axilla might be feasible.  
We therefore aimed to assess the reproducibility of the microbubble/ CEUS SLN 
core biopsy procedure by comparing the test accuracy of Centre 1 with a smaller 
population of consecutive patients from Centre 2 as well as 2 other UK centres 
using patients, which were selected on the basis of tumour clinico-pathological 
features.  We also examined the technical performance of individual radiologists 
at Centre 1. Lastly, we measured the volume of axillary metastases in patients 
from Centres 1 and 2 to determine the proportion of patients with a false 
negative microbubble/ CEUS SLN core biopsy who had 2 or more axillary LN 
macrometastases at the end of primary surgical treatment.  
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Methods 
Study Design 
Data was collected from 4 Breast Units across the UK (figure 1). In Centres 1 and 
2, patients were included with newly diagnosed breast cancer and an initial grey-
scale axillary ultrasound +/- biopsy of indeterminate/ abnormal LN (17) and 
only those with normal axillary imaging/ benign pathology proceeded to have a 
microbubble/ CEUS SLN core biopsy. At Centre 3, patients with newly diagnosed 
grade 2 or 3 invasive breast cancer and a normal grey-scale axillary ultrasound 
or indeterminate LN that were inadequate (not enough cells to make a diagnosis) 
or benign on cytology were included. At Centre 4, patients with newly diagnosed 
T2 or larger tumours, grade 2 or 3 invasive breast cancer with grey-scale 
ultrasound indeterminate axillary LN were included. Centres 3 and 4 selected 
patients at the discretion of the multi-disciplinary team. In all centres, pregnant 
patients and those with locally advanced/ metastatic disease were excluded. At 
Centre 1, 1361 consecutive patients were identified from a prospective database 
of patients having microbubble/ CEUS guided SLN core biopsy between 
December 2010 and November 2016. A proportion of this data (570 patients) 
has been previously analysed and published (14reference blinded for review). 
Retrospective data was collected on 376 consecutive patients from Centre 2 
between July 2010 and July 2014. Retrospective data was collected on 122 
selected patients from Centre 3 between July 2013 and December 2015. 
Prospective data was collected on 48 selected patients from Centre 4 between 
June 2013 and February 2015.  
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Identification and biopsy of SLN using intradermal microbubbles and CEUS 
Following a diagnosis of breast cancer, patients had an injection of ultrasound 
contrast agent (Sonovue, BRACCO Imaging S.p.A, Italy). 0.2ml of ultrasound 
contrast agent was injected intra-dermally in the periareolar, upper outer 
quadrant position using a 26G needle with a 1 ml tuberculin syringe at Centre 1, 
Centre 2 and Centre 3. Centre 4 used a 24G needle with a 1 ml tuberculin syringe.  
Lymphatic channels were visualised on contrast pulse sequencing and tracked 
into the axilla. Areas of contrast accumulation were also imaged with grey scale 
or live dual images (figure 2). Further injections of contrast up to 1ml and 3 
consecutive injections together with injection site massage for 10-30 seconds 
were performed if progress of contrast through the lymphatic vessels was slow/ 
not immediately evident. Once identified, the SLN was biopsied using a core 
biopsy technique, Centres 1 and 2 (Achieve automatic biopsy device, Carefusion, 
San Diego, California, USA. 2-3x 14-16G), Centre 3 (Trucut biopsy device, San 
Diego, California, USA. 3-4x 14G) and Centre 4 (Trucut biopsy device. 3-4x 18G).  
Microbubble/ CEUS guided SLN core biopsies were performed by consultant 
breast radiologists; 7 at Centre 1, 4 at Centre 2, 2 at Centre 3 and a single 
consultant breast radiologist at Centre 4. Three of the 7 radiologists at Centre 1 
also worked at Centre 2. Very rarely 2 SLN were visualised and both were 
biopsied at Centre 1, Centre 2 and Centre 3. At Centre 4, only the first enhancing 
SLN was biopsied. Centre 1 ultrasound examinations were performed with a 
Sequoia 512 Acuson (Siemens Medical Systems, Issaquah, Wash, USA) or LOGIQ 
9 (GE Healthcare, Fairfield, CT, USA) using a linear transducer operating at 4.5 to 
15MHz. Centre 2 ultrasound examinations were performed with a LOGIQ 9 using 
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a linear transducer operating at 4.5 to 15MHz, Centre 3 ultrasound examinations 
were performed with a Siemens Antaris or Acuson S1000 (Siemens Medical 
Systems, Issaquah, Wash, USA) and Centre 4 ultrasound examinations were 
performed with a Toshiba Aplio 500 (Toshiba Medical Systems Europe B.V., 
Zilverstraat 1, 2718RP, Zoetermeer, The Netherlands) using a mid-range linear 
probe (PLT-704SBT Linear). All ultrasound machines provided: conventional 
grey-scale, pulse-inversion harmonic grey scale, contrast specific sonographic 
imaging with live dual images of tissue only and contrast agent images. In order 
to reduce microbubble destruction, low mechanical index values were applied 
(MI: 0.1-0.4). Each centre performed histological analysis on biopsy samples. 
Centres 1 and 2 also used pancytokeratin (MNF116) immunohistochemical 
staining for patients with a lobular phenotype.  
 
Surgical Management of the axilla 
Initially, at Centre 1 and Centre 2 if the microbubble/ CEUS SLN core biopsy 
contained malignant cells, patients were advised to have an ipsilateral ALND. 
Later in the study period (Centre 1 and Centre 2) and throughout the study 
period at Centre 3 and Centre 4, to avoid surgical overtreatment, patients were 
recommended to have ALND only if a macrometastasis (>2mm) was seen in the 
core biopsy specimen and those with core biopsy isolated tumour cells (ITC) or 
micrometastases (<2mm) had SLNE.  Patients also had SLNE if the core biopsy 
identified indeterminate cellular changes, normal lymphoid tissue, inadequate 
tissue sampling or the patient declined primary ALND. Before surgery, patients 
had an injection of radioactive isotope (Nanocoll, G.E Healthcare, Chicago, USA), 
between 20 and 40mbeq in the peri-areolar, upper outer quadrant position. 
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Later that day or the following day, patients underwent surgical resection.  After 
anaesthetic induction, patients received a 2ml injection of blue dye (Bleu Patente 
V 2.5%, Guerbet, France) sub-dermally in the periareolar, upper outer quadrant 
position. A gamma probe (Navigator GPS, RMD Instruments, Watertown, USA) 
was used to identify SLN. All SLN within the axilla were excised and sent for local 
histological analysis including immunohistochemical staining for patients with a 
lobular phenotype at Centres 1 and 2. The total volume of axillary metastases at 
the end of surgical treatment was determined for each patient using the 
following scoring system: 1 (LN containing a macrometastasis), 0.5 (LN 
containing a micrometastasis) and 0.2 (LN containing isolated tumour cells)(12).  
 
Statistics 
The proportion of patients who had SLN identified was calculated. Using 
contingency tables, the sensitivity and specificity of a successful (LN tissue 
retrieved) CEUS guided SLN core biopsy, as the index test to identify SLN 
metastases in breast cancer patients with invasive disease was determined with 
axillary surgery (SLNE/ ALND) as the reference standard. The estimated values 
were calculated along with corresponding 95% confidence intervals (CI) 
illustrating the uncertainty in the results. All CI were calculated using the exact 
binomial method. The prevalence of SLN metastases in each population was 
derived from the reference standard. For centres 1 and 2, positive and negative 
predictive values were calculated directly, as they both employed consecutive 
enrolment so the study prevalence will be representative of the population of 
interest. For centres 3 and 4, which only included a non-randomly selected 
subset of eligible patients, Bayesian methods were used to calculate positive and 
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negative predictive values, using the prevalence from centre 1 (the largest centre 
with consecutive enrolment). The Mann-Whitney test was used to compare the 
volume of axillary metastases between patients with a false negative and true 
positive microbubble/ CEUS SLN biopsy. All analysis was completed using Stata 
software (Stata version 13.1; Stata Corp LP, College Station, Tx, USA). 
 
Ethics 
Kent Research Ethics Committee, UK approved the original trials at 
Centre 1 (reference numbers: 04/Q1801/25 and 11/H1101/1) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA) sanctioned the 
use of microbubbles by intraparenchymal injection (Eudract Number: 2004-
002423-41). All participating Centres were NHS Trusts and the New Procedures 
Committees at Centre 1, Centre 2, and Centre 3 and the Breast Services 
Committee at Centre 4 each approved the use of intradermal microbubbles and 
CEUS to identify and biopsy SLN in patients with breast cancer at their 
institution. 
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Results 
Visualisation and targeted core biopsy of SLN using intradermal 
microbubbles and CEUS  
A total of 1361 consecutive patients were identified from a prospectively 
maintained database at Centre 1. Complete data was not available for 12 patients 
and 1 patient had a fine needle aspiration biopsy (FNAB) rather than a core 
biopsy. Sentinel lymph nodes were clearly visualised by CEUS in 1216 of the 
1348 patients (90%). In the 132 cases where the intradermally injected 
microbubbles failed to traffic through lymphatics to identify SLN, 25 (19%) had 
previous surgery on the breast/ axilla, a post breast biopsy haematoma or 
malignant involvement of the nipple areolar complex.  A successful SLN core 
biopsy was achieved in 1083 of the 1348 patients (80%). The performance 
statistics of the 7 Centre 1 radiologists are presented in Table 1.  
A total of 376 patients were identified retrospectively at Centre 2. Complete data 
was not available for 15 patients, 3 patients had a FNAB and 15 patients did not 
have the microbubbles/ CEUS procedure. Sentinel lymph nodes were clearly 
visualised by CEUS in 290 of 343 patients (84.5%). A successful core biopsy of 
SLN was achieved in 273 of 343 patients (79.6%). 
At Centre 3, 121 patients were identified retrospectively. Complete data was not 
available for one patient. Sentinel lymph nodes were clearly visualised by CEUS 
in 109 of the 120 patients (90.8%). A successful core biopsy of SLN was achieved 
in 93 of 120 patients (77.5%). Prospective data was collected on 48 patients at 
Centre 4. There were technical problems with the initial 5 patients, as the 
lymphatics could not be visualised. However, once the settings on the ultrasound 
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machine were optimised, SLN were clearly visualised and successfully core 
biopsied in 38 of 43 patients (88%).  In all centres, there were no allergic 
reactions following the administration of contrast agent and only one significant 
bleeding complication (Centre 1) of a large haematoma after SLN core biopsy 
which was evacuated 2 weeks later at the time of primary surgical treatment. 
 
Identification of SLN metastases in patients with invasive breast cancer and 
a successful microbubble/ CEUS SLN core biopsy that underwent primary 
surgical treatment  
In patients with a successful microbubble/ CEUS SLN core biopsy, the following 
were excluded from final analysis; those with pre-invasive disease (DCIS), those 
who had primary systemic or endocrine therapy and patients who did not 
proceed with axillary surgery because of choice or inability to tolerate a general 
anaesthetic. At Centres 1 and 2, patients with un-biopsied grey-scale abnormal 
LN were excluded and 6 patients at Centre 1 were also excluded because of 
incomplete surgical data.  
At Centre 1, 816 of the 1083 patients with a successful microbubble/ CEUS SLN 
core biopsy went on to have primary surgical treatment. Evidence of a core 
biopsy tract was seen in the excised SLN of 656 (80%) patients, 127 (16%) 
patients did not have a core biopsy tract visualized in excised SLN, 2 (0.2%) 
patients had a core biopsy tract seen in non-SLN and data regarding the presence 
of a core biopsy tract was not recorded for 31 (3.8%) patients.  For the other 
centres; 215 of 273 patients (Centre 2), 80 of 93 patients (Centre 3) and 38 of 38 
patients (Centre 4) with a successful microbubble/ CEUS SLN core biopsy went 
on to have primary surgical treatment. Comprehensive data documenting 
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evidence of previous biopsy in excised SLN was not available for Centres 2, 3 and 
4. For each centre, the accuracy of a successful microbubble/ CEUS SLN core 
biopsy to identify SLN metastases in patients with invasive breast cancer is 
presented in Table 2. 
 
Volume of axillary metastases at the end of primary surgical treatment in 
patients with invasive breast cancer, radiologically normal axillary LN and 
a successful microbubble/ CEUS SLN core biopsy in Centres 1 and 2 
At Centre 1, 95 patients had a false negative microbubble/ CEUS SLN core biopsy 
with metastases found in the excised SLN. Of these, evidence of a core biopsy 
tract was seen in the excised SLN of 69 (72.6%) patients, 23 (24.2%) patients did 
not have a core biopsy tract visualised in excised SLN and data regarding the 
presence of a core biopsy tract was not recorded for 3 (3.2%) patients.    Sixty-
one patients (64%) with a false negative microbubble/ CEUS SLN core biopsy 
result went on to have a completion ALND and 34 (36%) had no further axillary 
surgery (axillary conservation). At the end of primary surgical treatment, 12 
patients (12.6%) were found to have 2 or more LN macrometastases and 82 
patients (87.4%) had less than 2 LN macrometastases. Of the 730 patients with 
an initial benign microbubble/ CEUS SLN core biopsy, only 12 (1.6%) had 2 or 
more LN macrometastases found at the end of primary surgical treatment (Table 
3). Eighty-four patients at Centre 1 had a true positive microbubble/ CEUS SLN 
core biopsy and 81 (96%) had an ALND whereas 3 (4%) had a SLNE. Of these 84 
patients, 42 (50%) had 2 or more axillary LN macrometastases at the end of 
primary surgical treatment.  
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At Centre 2, 28 patients had a false negative microbubble/ CEUS SLN core biopsy 
with metastases found in the excised SLN. Nineteen patients (68%) went on to 
have a completion ALND and 9 (32%) had axillary conservation. At the end of 
primary surgical treatment, 7 patients (25%) were found to have 2 or more 
axillary macrometastases and 22 patients (75%) had a malignant axillary LN 
score less than 2 or had ITC in multiple LN (one patient with ITC in 13 LN). Of the 
181 patients with an initial benign microbubble/ CEUS SLN core biopsy, 7 (4%) 
had 2 or more axillary macrometastases found at the end of primary surgical 
treatment (Table 4). Thirty-one patients at Centre 2 had a true positive 
microbubble/ CEUS SLN core biopsy and 30 (97%) had an ALND whereas 1 (3%) 
had a SLNE. Of these 31 patients, 14 (45%) had 2 or more axillary LN 
macrometastases at the end of primary surgical treatment.  
For both centres, at the end of surgical treatment the difference between the 
final malignant LN score of false negative versus true positive microbubble/ 
CEUS SLN core biopsies was statistically significant (figure 3). 
 
Discussion 
Despite the use of different ultrasound machines and variations in the methods 
and patient selection, the identification and core biopsy of SLN using intradermal 
microbubbles and CEUS in patients with breast cancer is a reproducible 
technique across multiple centres. Overall, the visualisation of SLN across the 4 
centres ranged from 84.5% to 90.8% and a successful core biopsy from 77.5% to 
88%. The sensitivities of a microbubble/ CEUS core biopsy as a test to identify 
SLN metastases in patients with invasive breast cancer at Centres 2, 3 and 4 
were within the 95% confidence intervals of Centre 1. FThe factors that 
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appeared to adversely affect the visualisation of SLN at Centre 1 included 
previous surgery and disease involvement of the nipple areolar complex.  
There is undoubtedly a learning curve associated with the proceduredure and 
familiarity with the equipment is important as demonstrated by the data from 
Centre 4 where they experienced technical problems with the first 5 patients. 
The performance of Centre 1 radiologists also highlightillustrate the distinct 
competencies of the 2 components of the procedure, namely SLN identification 
and SLN core biopsy. Even though identical ultrasound equipment and methods 
were used, the percentage of procedures with successful visualisation of SLN 
varied from 97% to 73%, which suggests either that not all radiologists at Centre 
1 received adequate procedural training before performing the test or some 
found it difficult to visualise microbubbles trafficking through lymphatic 
channels. Six of the 7 radiologists were fairly consistent in their ability to 
successfully core biopsy visualised SLN, but 1 obviously struggled and only 
successfully retrieved lymphoid tissue in 70% of cases. Anecdotally, most 
radiologists accustomed to the procedure recommend that novices observe 3 
cases, then perform 10 cases supervised before undertaking 30 independent 
procedures with an audit of their results. Once proficient, the whole procedural 
time is 15 to 30 minutes. 
 
There is scope to improve the technology of CEUS.  In swine models, LN 
metastases can be identified as areas devoid of contrast agent (11) and in a 
recent study of breast cancer patients, the sensitivity of CEUS as a test to identify 
SLN metastases using only enhancement patterns (no biopsy) was 81.8% (18). 
Innovations such as ultrafast ultrasound (19), super resolution imaging (20) and 
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improved lymphatic microbubble transit (21) may improve the ability of 
clinicians to visualise SLN and achieve a reliable standard. 
The sensitivityities of a microbubble/ CEUS core biopsy as a test to identify SLN 
metastases in patients with invasive breast cancer and a normal grey-scale 
axillary ultrasound/ benign axillary LN biopsy is consistently around 50% with 
at Centres 2, 3 and 4 were within the 95% confidence intervals of Centre 1. . The 
sensitivity of the technique as a test to identify SLN metastases is consistently 
around 50%, As grey-scale axillary ultrasound can usefully identify 
approximately 50% of LN metastases (22), the addition of a microbubble/ CEUS 
SLN core biopsy substantially increases the overall detection rate for metastatic 
axillary LN. Consequently, the negative predictive value of the test is high and 
<5% of patients (Centres 1 and 2) with a normal grey-scale ultrasound and 
benign microbubble/ CEUS SLN core biopsy had 2 or more LN macrometastases 
detected by axillary surgery. 
but because of the low prevalence of LN metastases in the studied patient 
groups, the negative predictive value of the test is high.  
We have previously speculated that the technique has a high false negative 
ratehigh false negative rate because the core biopsy fails to pick up small 
metastatic depositslow volume metastases in SLN (13) and this may be the 
reason why very few patients with a false negative microbubble/ CEUS core 
biopsy at Centres 1 and 2 had two or more axillary LN macrometastases found at 
the end of primary surgical treatment. Yet, retrieving more LN tissue with a 
vacuum-assisted biopsy technique does not appear to appreciably increase the 
sensitivity of microbubbles and CEUS (23). 
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  Alternatively, it is usual for only one SLN to be visualised and biopsied with 
CEUS but the median number of SLN retrieved with a surgical excision is 2 (3). In 
this series, 80% of surgically excised LN at Centre 1 showed evidence of a 
previous core biopsy and this proportion dropped to 72.6% in patients with a 
false negative benign microbubble/ CEUS SLN core biopsy. This raises the 
possibility that in the false negative cases, the second or subsequent SLN 
contained the metastases and perhaps more than one SLN should be actively 
sought with the microbubbles/ CEUS procedure. 
When compared to Centre 1, a higher proportion of Centre 2 patients with a 
benign microbubble/ CEUS SLN core biopsy had two or more axillary 
macrometastases found at the end of surgical treatment (1.8 vs 4%).  This may 
be related to the smaller patient sample size in Centre 2 or the higher prevalence 
of LN metastases in patients with a successful microbubble/ CEUS SLN core 
biopsy in Centre 2 (27% vs 22% at Centre 1). As the patient and 
clinicopathologic features of the tumours were similar in both centres, the 
greater prevalence of LN metastases at Centre 2 may be a consequence of a 
lower initial metastatic LN detection rate with grey-scale axillary ultrasound.  
The difference in the volume of axillary disease between patients with a false 
negative and true positive microbubble/ CEUS SLN core biopsy at the end of 
primary surgical treatment was statistically significant in Centres 1 and 2. When 
compared to the false negative groups in Centres 1 and 2, more patients with a 
true positive microbubble/ CEUS SLN core biopsy had complete axillary surgery 
(ALND) rather than axillary conservation (SLNE). The retrieval of a greater 
number of LN in the true positive groups from Centres 1 and 2 may therefore 
have increased the total number of axillary LN metastases found at the end of 
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surgical treatment and influenced the final metastatic score. However, in a 
previous publication from Centre 1 (14reference blinded for review) comparing 
only patients with complete axillary surgery (ALND), the difference in the 
volume of axillary disease between those with a false negative and true positive 
microbubble/ CEUS SLN core biopsy remained stastically significant. 
An argument against using CEUS to biopsy SLN in routine practice is that 
patients with a biopsy containing malignant cells are committed to a primary 
ALND for what may be a low burden of axillary disease. This can be mitigated 
against by offering SLNE to patients with micrometastases in the core biopsy 
specimen. It should also be noted that 50% of patients at Centre 1 and 45% of 
patients at Centre 2 with a true positive microbubble/ CEUS SLN core biopsy had 
2 or more axillary macrometastases found at the end of surgical treatment and 
therefore using the test for patients who are not eligible for axillary conservation 
(7) is beneficial.  
 
 
Conclusion 
In patients with breast cancer, the identification and biopsy of SLN using 
intradermally injected microbubbles and CEUS is a reproducible technique. The 
results of the American College of Surgeons Oncology group Z0011 trial (6) have 
changed practice by showing that loco-regional control of axillary metastases is 
not solely dependant upon surgical excision and residual disease can be treated 
with adjuvant therapy. In addition, anatomic staging of breast cancer is likely to 
become less relevant to treatment decisions as tumour genomic and molecular 
assays are better understood (24). Based on recent information obtained from 
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Centre 1, a SLNE costs 3.6x the cost of a microbubble/ CEUS SLN core biopsy 
(£671.63 vs £189 respectively). Omitting axillary surgery will improve theatre 
utilisation (potentially allowing more cases to be added to a list) as well as 
reducing the anaesthetic time for each patient. In the era of axillary conservation, 
molecular medicine and dwindling resources , which provides useful information 
that can influence treatment decisions. In the era of axillary conservation, the 
combination of grey-scale axillary ultrasound anda microbubble/ CEUS SLN core 
biopsy has the potential to succeed surgical staging of the axilla. Further work 
now needs to be undertaken to refine the procedure with protocols, standard 
setting and training. 
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Figure Captions 
Figure 1 
Diagram showing the selection and flow of participants from each centre 
through the study. Lymph node (LN), Sentinel Lymph Node (SLN), 
Contrast enhanced ultrasound (CEUS), Ductal Carcinoma in situ (DCIS), 
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isolated tumour cells (ITC), surgical sentinel lymph node biopsy (SLNB), 
axillary lymph node dissection (ALND) and POSNOC – (POsitive Sentinel 
NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or 
axillary radiotherapy. A randomised controlled trial of axillary treatment 
in women with early stage breast cancer who have metastases in one or 
two sentinel nodes). 
 
Figure 2 
A. Ultrasound contrast pulse sequencing image of a SLN (white arrow) 
after injection of intradermal microbubbles (between 0.2 and 1 ml 
injected using a 26G needle with 1ml tuberculin syringe) into the UOQ 
periareolar area of the breast. B. Grey scale ultrasound image of the same 
SLN as visualised in A. Images provided by Centre 3. 
 
Figure 3 
A. Volume of axillary disease at the end of primary surgical treatment for 
individual patients at Centres 1 and 2 who had a false negative (FN) or 
true positive (TP) microbubble/ CEUS core biopsy of SLN. Axillary lymph 
node dissection (ALND) and sentinel lymph node excision (SLNE). B. The 
total volume of axillary metastases at the end of surgical treatment was 
determined using a scoring system (isolated tumour cells = 0.2, each LN 
micrometastasis = 0.5 and each LN macrometastasis = 1). The Mann-
Whitney test was used to compare the volume of axillary metastases 
between patients with a false negative and true positive microbubble/ 
CEUS SLN biopsy in both centres.  
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Table 1 
Performance statistics of 7 consultant breast radiologists at Centre 1 
(Total 1349 of 1361 procedures). In 12 cases the data was incomplete and 
the name of the radiologist was not recorded. For radiologist no.1, one 
successful procedure was a fine needle aspiration biopsy rather than a 
core biopsy. 
 
Table 2 
Test accuracy of CEUS guided SLN biopsy using intradermally injected 
microbubbles in women with normal (centres 1 and 2) or indeterminate 
results from previous grey scale ultrasound (with or without previous 
biopsy). Reference standard is Sentinel Lymph node excision (SLNE) or 
axillary lymph node dissection (ALND). Positive predictive value (PPV) 
and negative predictive value (NPV) were calculated directly for centres 1 
and 2 who employed consecutive recruitment, and using Bayesian 
methods with 22% prevalence at centres 3 and 4 as these were not a 
consecutively or randomly selected group. True positive (TP), false 
positive (FP), true negative (TN) and false negative (FN). 
 
Table 3 
Age and clinicopathological characteristics of all patients at Centre 1 (first 
column) with a successful microbubble/CEUS SLN core biopsy before 
primary surgical treatment and Centre 1 patients with false negative 
microbubble/ CEUS SLN core biopsies sub-divided into micrometastases 
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(<2mm)/ isolated tumour cells (ITC), low volume metastases and high 
volume metastases identified at the end of primary surgical treatment. 
Data are expressed as n (%). Estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (Her2), 
invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC). 
 
Table 4 
Age and clinicopathological characteristics of all patients at Centre 2 (first 
column) with a successful microbubble/CEUS SLN core biopsy before 
primary surgical treatment and Centre 2 patients with false negative 
microbubble/ CEUS SLN core biopsies sub-divided into micrometastases 
(<2mm)/ isolated tumour cells (ITC), low volume metastases and high 
volume metastases identified at the end of primary surgical treatment. 
Data are expressed as n (%). Estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (Her2), 
invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC). 
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Table 1 
 Centre 1 – Consultant Breast Radiologists 
 
1 2 3 4 5 6 7 
 
Total Procedures 
 
276 
 
37 
 
501 
 
81 
 
116 
 
207 
 
131 
Procedures where core biopsy 
not attempted 
 
0 
(0%) 
 
 
0 
(0%) 
 
 
0 
(0%) 
 
 
2 
(2 .5%) 
 
 
0 
(0 %) 
 
 
0 
(0 %) 
 
 
1 
(0.8%) 
 
 
Procedures with successful 
visualisation of SLN 
 
 
269 
(97.5%) 
 
 
 
33 
(89.2%) 
 
 
 
457 
(91.2%) 
 
 
 
59 
(72.8%) 
 
 
 
94 
(81%) 
 
 
 
187 
(90.3%) 
 
 
 
118 
(90.1%) 
 
 
Procedures without SLN tissue 
retrieved 
 
 
1 
(0.4%) 
 
 
 
1 
(2.7%) 
 
 
 
64 
(12.8%) 
 
 
 
2 
(2.5%) 
 
 
 
10 
(8.6%) 
 
 
 
18 
(8.7%) 
 
 
 
34 
(26%) 
 
 
Successful retrieval of lymphoid 
tissue in those with visualised 
SLN 
 
 
268 
(99.6%) 
 
 
 
32 
(97%) 
 
 
 
393 
(86%) 
 
 
 
57 
(96.6%) 
 
 
 
84 
(89.4%) 
 
 
 
169 
(90.4%) 
 
 
 
84 
(71.2%) 
 
 
Total successful visualisation and 
268 
(97.1%) 
 
32 
393 
(78.4%) 
 
57 
 
84 
 
169 
 
84 
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core biopsy of SLN 
l  
(86.5%) 
 
(70.4%) 
 
(72.4%) 
 
(81.6%) 
 
(64.1%) 
 
 
 
 
 
 
Table 2 
Centre 
 
 
Prevalence 
of LN 
metastases 
TP FP TN FN Sensitivity Specificity PPV NPV 
 
1 
 
22% 
 
84 
 
2 
 
635 
 
95 
 
46.9% 
(39.4-55.5%) 
 
 
99.7 % 
(98.95-100%) 
 
 
97.7% 
(91.9-99.7%) 
 
87.0% 
(84.3-89.3% 
2 27% 31 3 153 28 
 
52.5%  
(39.1-65.7%) 
 
 
98.1% 
(94.5-99.6%)  
 
 
91.2% 
(76.3-98.1%)  
 
 
84.5%  
(78.4-89.5%) 
 
3 35% 13 0 52 15 
 
46.4% 
(27.5-66.1%)  
 
 
100%  
(93.2-100%) 
 
 
100%  
(75.3-100%) 
 
 
86.9% 
(82.4-90.3%)  
 
4 29% 5 1 26 6 
 
45.5% 
(16.7-76.6%)  
 
 
96.3%  
(81.0-99.9%) 
 
 
77.6%  
(31.3-96.3%) 
 
 
86.2 % 
(78.4 -91.5%) 
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Table 3 
  
Volume of disease at the end of surgical treatment (microbubble/ CEUS false negative core 
biopsy) 
  
Centre 1  All Patients 
Micrometastasis/ 
ITC 
Low (<2 LN macrometastases) High (2 or more LN macrometastases) 
          
Total number of patients 816 37 46 12 
     
  
15 (41%) ALND 34 (74%) ALND 12 (100%) ALND 
     Median age in years 
(range) 
61 (30-94) 61 (42-89) 55 (32-90) 53 (36-69) 
     
Receptor Status 
    
ER positive 707 (87%) 32 (86%) 40 (87%) 11 (92%) 
ER unknown 4 (0.4%) 0 0 0 
Her-2 positive 79 (10%) 3 (8%) 2 (4%) 1 (8%) 
Her-2 not recorded 13 (1.6%) 0 2 (4%) 0 
ER-/PR-/Her-2- 72 (10%) 4 (10.8%) 4 (9%) 0 
ER-/PR-/HER-2+ 28 (3%) 1 (2.7%) 1 (2%) 1 (8%) 
     
Invasive Tumour Size 
    
DCIS + microinvasion 5 (0.6%) 0 0 0 
T1 472 (58%) 19 (51%) 17 (37%) 4 (33%) 
T2 199 (24%) 10 (27%) 18 (39%) 5 (42%) 
T3 29 (4%) 5 (14%) 3 (7%) 1 (8%) 
Multifocal 111 (14%) 3 (8%) 8 (17%) 2 (17%) 
Unknown 0 0 0 0 
     
Tumour Grade 
    
Grade 1 180 (22%) 6 (16%) 7 (15%) 4 (33%) 
Grade 2 392 (48%) 20 (54%) 21 (46%) 6 (50%) 
Grade 3 209 (26%) 11 (30%) 14 (30%) 1 (8%) 
Mixed grade 29 (4%) 0 4 (9%) 1 (8%) 
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Unknown 1 (0.1%) 0 0 0 
     
Tumour Type 
    
IDC 660 (81%) 23 (62%) 38 (83%) 11 (92%) 
ILC 103 (13%) 11 (30%) 6 (13%) 1 (8%) 
Other 29 (4%) 1 (3%) 1 (2%) 0 
Mixed 17 (2%) 2 (5%) 1 (2%) 0 
Unknown 2 (0.2%) 0 0 0 
     
 
 
Table 4 
  Volume of disease at the end of surgical treatment (microbubble/ CEUS false negative core biopsy) 
  
Centre 2 All Patients 
Micrometastasis/ 
ITC 
Low (<2 LN macrometastases) High (2 or more LN macrometastases) 
     
Total number of patients 215 10 11 7 
     
  
2 (20%) ALND 10 (91%) ALND 7 (100%) ALND 
     Median age in years 
(range) 
64 (31-93) 63.5 (37-93) 62 (38-91) 55 (47-72) 
     
Receptor Status 
    
ER positive 176 (82%) 10 (100%) 8 (73%) 6 (86%) 
ER unknown 6 (3%) 0 1 (9%) 1 (14%) 
Her-2 positive 29 (13%) 1 (10%) 0 1 (14%) 
Her-2 not recorded 8 (4%) 0 1 (9%) 1 (14%) 
ER-/PR-/Her-2- 23 (11%) 0 1 (9%) 0 
ER-/PR-/HER-2+ 10 (5%) 0 0 0 
     
Invasive Tumour Size 
    
DCIS + microinvasion 0 0 0 0 
T1 118 (55%) 2 (20%) 6 (55%) 2 (29%) 
T2 71 (33%) 6 (60%) 4 (36%) 5 (71%) 
T3 9 (4%) 0 0 0 
Multifocal 17 (8%) 2 (20%) 0 0 
Unknown 0 0 1 (9%) 0 
     
Tumour Grade 
    
Grade 1 35(16%) 1 (10%) 0 2 (29%) 
Grade 2 102 (47%) 6 (60%) 5 (45.5%) 1 (14%) 
Grade 3 68 (32%) 2 (20%) 4 (36%) 4 (57%) 
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Mixed grade 4 (2%) 0 0 0 
Unknown 6 (3%) 0 2 (18%) 0 
     
Tumour Type 
    
IDC 160 (74%) 7 (70%) 8 (73%) 5 (71%) 
ILC 24 (11%) 2 (20%) 1 (9%) 0 
Other 16 (7%) 0 0 0 
Mixed 13 (6%) 1 (10%) 1 (9%) 2 (29%) 
Unknown 2 (1%) 0 1 (9%) 0 
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Centre 2 (n=375)
Retrospective data
Centre 3 (n=122)
Retrospective data
Centre 4 (n=48)
Prospective data
Selected patients 
newly diagnosed with  
invasive breast cancer 
T2 or larger tumours, 
grade 2 or 3 with grey-
scale ultrasound 
indeterminate axillary 
LN with or without 
inadequate LN 
cytology. 
SLN identified and biopsied with 
intradermally injected 
microbubbles and CEUS
(Index Test) 
Benign
ITC or 
micrometastases in 
core biopsy 
specimen
Macrometastasis in 
core biopsy 
specimen
1 to 2 weeks later
SLNB
(Reference standard)
ALND
(Reference standard)
Benign
Macrometastases
Adjuvant Treatment
Suitable for axillary 
conservation
POSNOC
Trial
Excluded from further 
analysis;
Neo-adjuvant therapy
No axillary surgery
Incomplete data
DCIS
Initially at 
Centres 1& 2
Selected patients 
newly diagnosed with 
grade 2 or 3 invasive 
breast cancer with 
grey-scale ultrasound 
normal LN or 
indeterminate LN with 
inadequate or benign 
cytology. 
Sequential patients 
newly diagnosed with 
early breast cancer 
with morphologically 
normal LN seen on  
grey-scale axillary 
ultrasound or benign 
biopsy of 
morphologically 
abnormal LN. 
Sequential patients 
newly diagnosed with 
early breast cancer 
with morphologically 
normal LN seen on  
grey-scale axillary 
ultrasound or benign 
biopsy of 
morphologically 
abnormal LN. 
Centre 1 (n=1361)
Prospective database
Figure 1
Figure 2
A B
Figure 2
Centre 1 Centre 2
816 215
Successful microbubble/ CEUS SLN
core biopsy and primary surgical
treatment (number of patients).
FN 
n = 95
TP 
n = 84
FN 
n = 28
TP 
n = 31
ALND
n = 61
(64%)
SLNE
n = 34
(36%)
>2 LN 
macrometastases
n = 12
(12.6%)
ALND
n = 81
(96%)
SLNE
n = 3
(4%)
>2 LN 
macrometastases
n = 42
(50%)
ALND
n = 19
(68%)
ALND
n = 30
(97%)
SLNE
n = 9
(32%)
SLNE
n = 1
(3%)
>2 LN 
macrometastases
n = 7
(25%)
>2 LN 
macrometastases
n = 14
(45%)
Centre
no. of true 
positives
Median LN 
score (IQR)
no. of false 
negatives
Median LN 
score (IQR)
P-value
1 84 1.75 (1 – 3) 95 1 (0.5 – 1) <0.0005
2 31 1.5 (1 – 2) 28 1 (0.5 – 2) 0.01
A
B
Axillary
Surgery
Figure 3
